Cargando…
Tolvaptan and its potential in the treatment of hyponatremia
Tolvaptan is a selective arginine vasopressin (AVP) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia. Currently the orally active medication is in the final stages prior to approval by the FDA for outpatient therapy. It appears to be...
Autores principales: | Dixon, Megan B, Lien, Y Howard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643096/ https://www.ncbi.nlm.nih.gov/pubmed/19337422 |
Ejemplares similares
-
Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011) -
Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
por: Nodari, Savina, et al.
Publicado: (2010) -
Tolvaptan in the Treatment of Acute Hyponatremia Associated with Acute Kidney Injury
por: Gopinath, Shilpa, et al.
Publicado: (2013) -
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018) -
Management of hyponatremia associated with acute porphyria—proposal for the use of tolvaptan
por: Solares, Isabel, et al.
Publicado: (2020)